CNB0.F FORTRESS BIOTECH.PRF.A 25

Healthcare Biotechnology Frankfurt Exchange
- EUR
Market cap
-
P/E
-
P/B
-
ROE
133.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CNB0.F undervalued?

Graham number

The Graham number of FORTRESS BIOTECH.PRF.A 25 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

FORTRESS BIOTECH.PRF.A 25 fundamental analysis

No fundamental analysis for FORTRESS BIOTECH.PRF.A 25 yet.

FORTRESS BIOTECH.PRF.A 25 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About FORTRESS BIOTECH.PRF.A 25

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of les…

Full company profile